Astellas

Amgen and Astellas announce Japan alliance

Wednesday, May 29, 2013 02:48 PM

Amgen, an independent biotechnology company, and Astellas Pharma, a Tokyo-based global pharmaceutical company, have entered into an alliance to provide new medicines to help address serious unmet medical needs of Japanese patients.

More... »

Astellas outlines plan to reshape its research framework, reallocate resources

Tuesday, May 14, 2013 02:44 PM

Tokyo-based Astellas Pharma has announced plans to reshape its research framework by introducing new initiatives to enhance the ability to generate innovative drugs.

More... »

High school junior Natalie Ng wins International BioGENEius Challenge

Friday, April 26, 2013 11:42 AM

Natalie Ng, a junior at Monta Vista High School in Cupertino, Calif., won the International BioGENEius Challenge, the premier competition for high school students that recognizes outstanding research in biotechnology. Ng’s research in breast cancer and biomarkers helped her stand out from the 13 other finalists from across the U.S., Canada and Australia competing for the Challenge's top prize, a $7,500 cash award.

More... »

Japan establishes global fund for R&D of new medicines, vaccines, diagnostics

Wednesday, April 10, 2013 10:15 AM

Japan’s first public-private partnership to advance the development of new health technologies for the developing world The Global Health Innovative Technology Fund (GHIT Fund) has officially launched. The GHIT Fund has been established to advance the R&D of new medicines, vaccines and diagnostics to fight infectious diseases in the developing world.

More... »

Astellas inks two new dengue virus research collaborations

Monday, March 25, 2013 10:30 AM

Global pharmaceutical company Astellas Pharma has signed collaborative research agreements with both the Nagasaki University and the Tokyo Institute of Technology, both located in Japan, regarding the dengue virus.

More... »

Astellas, Ambit terminate collaboration on FLT3 kinase inhibitors

Wednesday, March 13, 2013 10:39 AM

Tokyo-based Astellas Pharma and San Diego-based Ambit Biosciences will end their collaboration for the joint development and commercialization of FMS-like tyrosine kinase-3 (FLT3) inhibitors, including quizartinib, effective September 3, 2013.

More... »

AVEO, Astellas initiate phase II trial in triple negative breast cancer

Monday, December 3, 2012 02:11 PM

AVEO Oncology, a Cambridge, Mass.-based cancer therapeutics company, and Astellas Pharma, A Tokyo-based a pharmaceutical company, have initiated patient enrollment in a phase II trial evaluating the efficacy of tivozanib, an investigational drug, in combination with paclitaxel in patients with locally recurrent or metastatic triple negative breast cancer.

More... »

Janssen to develop, commercialize Astellas’ ASP015K for immunologic diseases

Wednesday, October 3, 2012 09:52 AM

Janssen Biotech and Astellas Pharma have formed a license agreement whereby Janssen gains the exclusive right to develop and commercialize ASP015K, an Astellas compound, worldwide except for Japan.

More... »

Abbott, Astellas collaborate on CMV vaccine trial

Monday, September 10, 2012 11:03 AM

Abbott has signed an agreement to collaborate with Astellas Pharma Global Development in a phase III clinical trial for ASP0113 (TransVax), an investigational vaccine licensed from Vical for preventing cytomegalovirus (CMV) reactivation in transplant patients.

More... »

Astellas Pharma Europe appoints Wood as senior director, market access

Monday, August 20, 2012 03:21 PM

Astellas Pharma Europe, the European subsidiary of Tokyo-based Astellas Pharma, has appointed Dr, Susan Wood as senior director, market access.

More... »